

Attorney Docket No.:       **DEX0499US.NP**  
Inventors:                   **Fan et al.**  
Serial No.:                  **10/593,799**  
Filing Date:               **August 6, 2007**  
Page 3

**Amendments to the Specification:**

At page 88, please replace the paragraph beginning at line 2 with the following:

A PCR fragment of cDNA encoding Thr25 to Gly420 of Lng105 was introduced into an expression vector via recombination. The construct was cloned in-frame to a stanniocalcin 1 secretion signal peptide (Met1 to Gln23) at the N-terminal end and a six-histidine tag, located at the C-terminal end. Additionally, due to polylinkers in the vector the construct contains 4 residues, SRTL (SEQ ID NO:3), following the first 18 amino acid STC secretion signal and 11 residues, ASYPYDVPDYA (SEQ ID NO:4), before the six-histidine tag. The resulting Lng105 construct was expressed as six-histidine tagged protein of 438 amino acids. The recombinant plasmid was used to transfect HEK 293F cells for producing proteins.

At page 102, please replace the paragraph beginning at line 4 with the following:

These deposits were made with the American Type Culture Collection at 10801 University Blvd, Manassas VA 20110-2209, USA under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure and the Regulations there under (Budapest Treaty). This assures maintenance of viable cultures for 30 years from the date of deposit. The organisms will be made available by ATCC under the terms of the Budapest Treaty, and subject to an agreement between diaDexus, Inc. and ATCC, which assures permanent and unrestricted availability of the progeny of the

Attorney Docket No.: **DEX0499US.NP**  
Inventors: **Fan et al.**  
Serial No.: **10/593,799**  
Filing Date: **August 6, 2007**  
Page 4

cultures to the public upon issuance o the pertinent U.S. patent or upon laying open to the public of any U.S. or foreign patent application, whichever comes first, and assures availability of the progeny to one determined by the U.S. Commissioner of Patents and Trademarks to be entitled thereto according to 35 USC §122 and the Commissioner's rules pursuant thereto (including 37 CFR §1.14 with particular reference to 886 OG 638).